Browse studies

Find your next paid study

17 recruiting studies matching your filters

Newest first Highest paying

Pathophysiologic Mechanisms Leading to Intrahepatic Fat Accumulation in Obese Youth

The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.

NAFLD

Estimated

~$10 – $750

Yale UniversityNCT04634643

Observational

Reversal of Lipid-Induced Insulin Resistance

The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity …

Insulin ResistanceNAFLD

Estimated

~$10 – $6,250

Yale UniversityNCT02193295

Phase 1

Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)

Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S…

NAFLDPCOS

Estimated

~$10 – $5,625

University of California, San FranciscoNCT05979389

Phase 2

A Randomized Double Blinded Placebo-Controlled Trial of Semaglutide to Prevent Weight Gain Following Liver Transplantation

In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after…

NAFLD

Estimated

~$10 – $6,250

University of VirginiaNCT05424003

Phase 1

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steato…

Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisMetabolic Dysfunction-associated Steatotic Liver Disease (MASLD)+1 more

Estimated

~$10 – $8,750

Corcept TherapeuticsNCT07553663

Phase 2

Clinical Trial of Oral Digoxin In NASH (CODIN)

Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment f…

NASHNAFLDMASH - Metabolic Dysfunction-Associated Steatohepatitis+5 more

Estimated

~$10 – $6,250

Yale UniversityNCT06588699

Phase 3

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months …

Hepatic SteatosisNAFLDAdolescent Obesity

Estimated

~$10 – $6,250

University of Colorado, DenverNCT05935826

Accurate Point of Care Liver Disease Diagnostics

This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in whi…

MASLDMASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)NAFLD+1 more

Estimated

~$10 – $750

University of California, San DiegoNCT07518784

Androgens and Nonalcoholic Fatty Liver Disease (NAFLD) In Reproductive-Aged Women With and Without Polycystic Ovary Syndrome (PCOS)

The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when …

PCOSNAFLDNASH

Estimated

~$10 – $675

University of California, San FranciscoNCT06124261

Phase 2

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety o…

Non-Alcoholic Fatty Liver DiseaseNAFLDPediatric NAFLD

Estimated

~$10 – $7,500

Justin RyderNCT03867487

Observational

Testing the Effectiveness of NAFLD Clinical Care Pathway in VA Primary Care

Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrh…

NAFLDMASLD

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT06671886

Observational

A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization, to Promote Short-term Weight Loss in Obese Patients With Nonalcoholic Steatohepatitis (NASH) and Thereby Improve NASH

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is n…

ObesityWeight LossBody Weight+3 more

Estimated

~$10 – $7,500

Keith Pereira, MD:NCT02933554